Leveraging Diagnostics in a Biotech World
Executive Summary
Corixa's recent deal with Ortho-Clinical Diagnostics brings Ortho exclusive worldwide diagnostics rights to Corixa's breast cancer genes and antigens and helps Ortho gain a foothold in the emerging area of molecular testing. It also illustrates how biotech companies caught up in long-term programs for therapeutics can capture some near-term value. While Corixa's lead drug is delayed at the FDA, the deal gives the company a source of revenues that may be small but is at least real.You may also be interested in...
Diagnostics as Venture Investments
Will the emergence of new biological targets as a result of genomics and proteomics change venture investors' prejudice against diagnostics? No--or at least not until patented biomarkers can be tied more closely to the cause of the disease and to a therapeutic that treats it.
UniQure Aiming To Be First With Hemophilia B Gene Therapy
Company says it has learnt from gene therapy flop Glybera, and claims best-in-class status for viral vector.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports